ClinicalTrials.gg
CompletedNCT04346199CALAVIUpdated Sep 17, 2021Results posted

Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.

A Phase 2 interventional study of Acalabrutinib in COVID-19, sponsored by AstraZeneca. Completed at 50 sites in 14 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2021-09-17.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
177
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in COVID-19 by AstraZeneca — 1 open to participants now, 1 under way, 1 of them phase 3. COVID-19 · AstraZeneca.

Enrollment
13th of 26
177 · median 147
Started
2020
with 11 others
Phase 2
5 of 43
none open now
Registered
1st of 43
by date

Among the 43 studies in COVID-19 by AstraZeneca, this one is the 13th largest by enrollment of the 26 interventional ones that give a count, is one of 12 that started in 2020, is one of 5 in phase 2, and was the 1st registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

1 of the 43 studies in COVID-19 by AstraZeneca is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in COVID-19 by AstraZeneca, or all of them as a file.
02

Study summary

CALAVI will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together with Best Supportive Care in the treatment of COVID-19.

03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • 2019 novel coronavirus disease
  • Acalabrutinib
  • Btk inhibitor
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to understand the purpose and risks of the study and provide signed and dated or have a legal representative provide consent and authorization to use protected health information (in accordance with national and local patient privacy regulations)
  2. Men and women ≥18 years of age at the time of signing the informed consent form
  3. Confirmed infection with SARS-CoV-2 confirmed per World Health Organization (WHO) criteria (including positive RT-PCR nucleic acid test of any specimen [eg, respiratory, blood, urine, stool, or other bodily fluid]) within 4 days of randomization
  4. COVID-19 pneumonia (documented radiographically) requiring hospitalization and oxygen saturation \<94% on room air or requires supplemental oxygen
  5. Able to swallow pills
  6. Willing to follow guidelines

Exclusion criteria

Exclusion Criteria:

  1. Respiratory failure at time of screening due to COVID-19
  2. Known medical resuscitation within 14 days of randomization
  3. Pregnant or breast feeding
  4. Suspected uncontrolled active bacterial, fungal, viral, or other infection (besides infection with SARS-CoV-2)
  5. (ALT), aspartate aminotransferase (AST) and/or ≥ 3x (ULN) and/or severe hepatic impairment detected within 24 hours at screening (per local lab)
  6. Uncontrolled or untreated symptomatic arrhythmias, myocardial infarction within the last 6 weeks, or congestive heart failure ( Grade 3 or 4). Exception: Subjects with controlled, asymptomatic atrial fibrillation during screening are allowed to enroll
  7. Treatment with a strong cytochrome P450 (CYP)3A inhibitor (within 14 days before first dose of study drug) or inducer (within 7 days before first dose of study drug).
  8. Requires treatment with proton-pump inhibitors (PPIs; eg, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Subjects receiving PPIs who switch to H2-receptor antagonists or antacids are eligible for enrollment in this study
  9. Received oral antirejection or immunomodulatory drugs (eg, anticytokines, Btk inhibitors, JAK inhibitors, PI3K inhibitors) within 30 days before randomization on study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
177 participants (actual)

Study arms

  • Experimental
    Arm 1

    Acalabrutinib+ Best Supportive Care

    Drug: Acalabrutinib

  • No intervention
    Arm 2

    Best Supportive Care

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Alive and Free of Respiratory Failure at Day 14

    Respiratory failure, is defined based on resource utilization of any of the following modalities: a) Endotracheal intubation and mechanical ventilation b) Oxygen delivered by high-flow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates \>20 L/min with fraction of delivered oxygen ≥0.5) c) Non-invasive positive pressure ventilation or continuous positive airway pressure d) Extracorporeal membrane oxygenation

    Time frame: At Day 14

Secondary outcomes

  1. Number of Participants With Adverse Events and Serious Adverse Events

    Time frame: Screening to 28 (+3) days after last dose of acalabrutinib (for acalabrutinib + BSC participants) or to 38 (+3) days after randomization (for BSC alone participants)

  2. Percentage of Participants Alive and Free of Respiratory Failure at Day 28

    Respiratory failure, is defined based on resource utilization of any of the following modalities: a) Endotracheal intubation and mechanical ventilation b) Oxygen delivered by highflow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates \>20 L/min with fraction of delivered oxygen ≥0.5) c) Non-invasive positive pressure ventilation or continuous positive airway pressure d) Extracorporeal membrane oxygenation

    Time frame: At Day 28

  3. Percent Change From Baseline in C-reactive Protein.

    Baseline is defined as the result obtained on the date of randomization. If no result was obtained on the date of randomization, the last result prior to the date of randomization is used. Percent change from baseline at Day X is calculated by multiplying the following result by 100%: (Day X value - Baseline value)/Baseline value. The mean of this result for all analyzed patients is taken to get the mean percent change from baseline.

    Time frame: Days 3, 5, 7, 10, 14, 28

  4. Percent Change From Baseline in Ferritin

    Baseline is defined as the result obtained on the date of randomization. If no result was obtained on the date of randomization, the last result prior to the date of randomization is used. Percent change from baseline at Day X is calculated by multiplying the following result by 100%: (Day X value - Baseline value)/Baseline value. The mean of this result for all analyzed patients is taken to get the mean percent change from baseline.

    Time frame: Days 3, 5, 7, 10, 14, 28

  5. Percent Change From Baseline in Absolute Lymphocyte Count

    Baseline is defined as the result obtained on the date of randomization. If no result was obtained on the date of randomization, the last result prior to the date of randomization is used. Percent change from baseline at Day X is calculated by multiplying the following result by 100%: (Day X value - Baseline value)/Baseline value. The mean of this result for all analyzed patients is taken to get the mean percent change from baseline.

    Time frame: Days 3, 5, 7, 10, 14, 28

  6. Overall Survival

    Median overall survival, calculated using the Kaplan-Meier technique. Confidence interval for median overall survival (days) is derived based on Brookmeyer-Crowley method with log-log transformation.

    Time frame: From randomization until 90 days after randomization. Safety Issue:

  7. Percentage of Participants Alive and Discharged From ICU

    Time frame: At Day 14 and at Day 28

  8. Time From Randomization to First Occurrence of Respiratory Failure or Death on Study Due to Any Cause

    Median time to first occurrence of respiratory failure or death, calculated using the Kaplan-Meier technique. Confidence interval for median overall survival (days) is derived based on Brookmeyer-Crowley method with log-log transformation.

    Time frame: From randomization to 28 days after randomization.

  9. Number of Days Alive and Free of Respiratory Failure

    Respiratory failure, is defined based on resource utilization of any of the following modalities: a) Endotracheal intubation and mechanical ventilation b) Oxygen delivered by highflow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates \>20 L/min with fraction of delivered oxygen ≥0.5) c) Non-invasive positive pressure ventilation or continuous positive airway pressure d) Extracorporeal membrane oxygenation

    Time frame: From randomization to 28 days after randomization.

  10. Number of Days With Respiratory Failure

    Respiratory failure, is defined based on resource utilization of any of the following modalities: a) Endotracheal intubation and mechanical ventilation b) Oxygen delivered by high-flow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates \>20 L/min with fraction of delivered oxygen ≥0.5) c) Non-invasive positive pressure ventilation or continuous positive airway pressure d) Extracorporeal membrane oxygenation For participants who die (due to any cause) prior to Day 28, days from death to Day 28 are counted as days with respiratory failure. For participants in hospital and experiencing respiratory failure at the time they withdraw from the study, days from last known status to Day 28 are counted as days with respiratory failure.

    Time frame: From randomization to 28 days after randomization.

  11. Number of Days Hospitalized

    For this summary, the hospitalization must be considered clinically indicated to count as a day hospitalized. For participants who die (due to any cause) prior to Day 28, days from death to Day 28 are counted as days hospitalized. For participants in hospital at the time they withdraw from the study, days from last known status to Day 28 are counted as days hospitalized.

    Time frame: From randomization to 28 days after randomization.

  12. Number of Days in ICU

    For this summary, the ICU stay must be considered clinically indicated to count as a day in ICU. For participants who die (due to any cause) prior to Day 90, days from death to Day 90 are counted as days in ICU.

    Time frame: From randomization to 90 days after randomization.

  13. Number of Days Alive Outside of Hospital

    Time frame: From randomization to 28 days after randomization.

  14. Number of Days Alive Outside of Hospital

    Time frame: From randomization to 90 days after randomization.

  15. Percent Change From Baseline in Oxygenation Index

    Baseline is defined as the result obtained on the date of randomization. Percent change from baseline at Day X is calculated by multiplying the following result by 100%: (Day X value - Baseline value)/Baseline value. The mean of this result for all analyzed patients is taken to get the mean percent change from baseline.

    Time frame: Days 3, 5, 7, 10, 14, 28

  16. Time From Randomization to Clinical Improvement of at Least 2 Points on a 9-point Category Ordinal Scale

    9-point category ordinal scale: 0. \* Uninfected, no clinical or virological evidence of infection 1. Ambulatory, no limitation of activities 2. Ambulatory, limitation of activities 3. Hospitalized - mild disease, no oxygen therapy 4. Hospitalized - mild disease, oxygen by mask or nasal prongs 5. Hospitalized - severe disease, non-invasive ventilation or high flow oxygen 6. Hospitalised - severe disease, intubation and mechanical ventilation 7. Hospitalized - severe disease, ventilation and additional organ support, such as pressors, renal replacement therapy, extracorporeal membrane oxygenation 8. Death Median time to first occurrence of respiratory failure or death, calculated using the Kaplan-Meier technique. Confidence interval for median overall survival (days) is derived based on Brookmeyer-Crowley method with log-log transformation.

    Time frame: From randomization to 28 days after randomization.

  17. Pharmacokinetics of Acalabrutinib

    Summary of plasma concentrations (ng/mL) of acalabrutinib

    Time frame: Day 3 and Day 7

  18. Pharmacokinetics of ACP-5862

    Summary of plasma concentrations (ng/mL) of ACP-5862

    Time frame: Day 3 and Day 7

07

Results

Posted Sep 13, 2021
Limitations and caveats
Improvements in BSC (use of corticosteroids and antivirals) have led to a substantial reduction in mortality and morbidity in patients hospitalized with COVID-19, which, in turn, minimizes the impact that additional treatment regimens can have on patient prognosis and recovery. In addition, variability in patient population and the performance of BSC across the globe poses challenges to demonstrate benefit.

Participant flow

All participants had COVID-19 pneumonia (documented radiographically) requiring hospitalization and were recruited from the following countries: South Africa; India; Turkey; Japan; Russian Federation; France; Italy; Brazil; Argentina; Peru; Mexico; Chile. The first participant was randomized on 15 June 2020 and the last participant was randomized on 17 August 2020.

Participant flow — Overall Study
MilestoneAcalabrutinib + BSCBSC Alone
Started8988
Completed7477
Not completed1511
Withdrew: Death89
Withdrew: Lost to follow-up01
Withdrew: Study terminated by sponsor incorrectly entered in database - participants completed the study20
Withdrew: Withdrawal by subject51

Outcome measures

PrimaryPercentage of Participants Alive and Free of Respiratory Failure at Day 14

Respiratory failure, is defined based on resource utilization of any of the following modalities: a) Endotracheal intubation and mechanical ventilation b) Oxygen delivered by high-flow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates \>20 L/min with fraction of delivered oxygen ≥0.5) c) Non-invasive positive pressure ventilation or continuous positive airway pressure d) Extracorporeal membrane oxygenation

Time frame:
At Day 14
Reported as:
Number · Percentage of participants
Percentage of Participants Alive and Free of Respiratory Failure at Day 14
Percentage of participantsAcalabrutinib + BSCBSC Alone
Percentage of Participants Alive and Free of Respiratory Failure at Day 1483.1 (74.8 to 91.5)90.9 (84.3 to 97.5)
SecondaryNumber of Participants With Adverse Events and Serious Adverse Events
Time frame:
Screening to 28 (+3) days after last dose of acalabrutinib (for acalabrutinib + BSC participants) or to 38 (+3) days after randomization (for BSC alone participants)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events and Serious Adverse Events
ParticipantsAcalabrutinib + BSCBSC Alone
Any Adverse Event4337
Any Serious Adverse Event72
SecondaryPercentage of Participants Alive and Free of Respiratory Failure at Day 28

Respiratory failure, is defined based on resource utilization of any of the following modalities: a) Endotracheal intubation and mechanical ventilation b) Oxygen delivered by highflow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates \>20 L/min with fraction of delivered oxygen ≥0.5) c) Non-invasive positive pressure ventilation or continuous positive airway pressure d) Extracorporeal membrane oxygenation

Time frame:
At Day 28
Reported as:
Number · Percentage of participants
Percentage of Participants Alive and Free of Respiratory Failure at Day 28
Percentage of participantsAcalabrutinib + BSCBSC Alone
Percentage of Participants Alive and Free of Respiratory Failure at Day 2884.3 (76.1 to 92.4)88.6 (81.4 to 95.8)
SecondaryPercent Change From Baseline in C-reactive Protein.

Baseline is defined as the result obtained on the date of randomization. If no result was obtained on the date of randomization, the last result prior to the date of randomization is used. Percent change from baseline at Day X is calculated by multiplying the following result by 100%: (Day X value - Baseline value)/Baseline value. The mean of this result for all analyzed patients is taken to get the mean percent change from baseline.

Time frame:
Days 3, 5, 7, 10, 14, 28
Reported as:
Mean · Percent change
Percent Change From Baseline in C-reactive Protein.
Percent changeAcalabrutinib + BSCBSC Alone
Day 3-15.06 ± 95.82-15.25 ± 91.61
Day 5-12.48 ± 113.38-41.07 ± 92.59
Day 7-45.71 ± 106.84-23.41 ± 223.06
Day 10/ Discharge (last post-baseline assessment if discharged from hospital prior to Day 10)-16.84 ± 194.71-29.32 ± 166.35
Day 10-35.53 ± 126.84-23.41 ± 203.02
Day 14-12.49 ± 187.37-17.26 ± 256.87
Day 28-30.28 ± 192.90-63.74 ± 75.28
SecondaryPercent Change From Baseline in Ferritin

Baseline is defined as the result obtained on the date of randomization. If no result was obtained on the date of randomization, the last result prior to the date of randomization is used. Percent change from baseline at Day X is calculated by multiplying the following result by 100%: (Day X value - Baseline value)/Baseline value. The mean of this result for all analyzed patients is taken to get the mean percent change from baseline.

Time frame:
Days 3, 5, 7, 10, 14, 28
Reported as:
Mean · Percent change
Percent Change From Baseline in Ferritin
Percent changeAcalabrutinib + BSCBSC Alone
Day 39.84 ± 92.666.49 ± 40.23
Day 512.92 ± 105.09-12.76 ± 43.18
Day 7-8.93 ± 53.52-8.79 ± 36.40
Day 10/ Discharge (last post-baseline assessment if discharged from hospital prior to Day 10)-9.09 ± 58.851.35 ± 125.95
Day 10-5.99 ± 73.716.84 ± 178.23
Day 14-18.81 ± 67.85-26.80 ± 46.10
Day 28-66.82 ± 18.24-66.05 ± 21.67
SecondaryPercent Change From Baseline in Absolute Lymphocyte Count

Baseline is defined as the result obtained on the date of randomization. If no result was obtained on the date of randomization, the last result prior to the date of randomization is used. Percent change from baseline at Day X is calculated by multiplying the following result by 100%: (Day X value - Baseline value)/Baseline value. The mean of this result for all analyzed patients is taken to get the mean percent change from baseline.

Time frame:
Days 3, 5, 7, 10, 14, 28
Reported as:
Mean · Percent change
Percent Change From Baseline in Absolute Lymphocyte Count
Percent changeAcalabrutinib + BSCBSC Alone
Day 331.74 ± 59.3236.82 ± 79.91
Day 555.79 ± 101.5787.25 ± 140.37
Day 751.72 ± 91.8279.33 ± 119.73
Day 10/ Discharge (last post-baseline assessment if discharged from hospital prior to Day 10)78.34 ± 95.8899.65 ± 149.02
Day 1098.55 ± 113.6683.08 ± 105.56
Day 1474.65 ± 124.4791.58 ± 123.63
Day 2889.35 ± 100.2496.62 ± 97.30
SecondaryOverall Survival

Median overall survival, calculated using the Kaplan-Meier technique. Confidence interval for median overall survival (days) is derived based on Brookmeyer-Crowley method with log-log transformation.

Time frame:
From randomization until 90 days after randomization. Safety Issue:
Reported as:
Median · Days
Overall Survival
DaysAcalabrutinib + BSCBSC Alone
Overall SurvivalNA (NA to NA)NA (NA to NA)
SecondaryPercentage of Participants Alive and Discharged From ICU
Time frame:
At Day 14 and at Day 28
Reported as:
Number · Percentage of participants
Percentage of Participants Alive and Discharged From ICU
Percentage of participantsAcalabrutinib + BSCBSC Alone
At Day 1478.789.8
At Day 2883.187.5
SecondaryTime From Randomization to First Occurrence of Respiratory Failure or Death on Study Due to Any Cause

Median time to first occurrence of respiratory failure or death, calculated using the Kaplan-Meier technique. Confidence interval for median overall survival (days) is derived based on Brookmeyer-Crowley method with log-log transformation.

Time frame:
From randomization to 28 days after randomization.
Reported as:
Median · Days
Time From Randomization to First Occurrence of Respiratory Failure or Death on Study Due to Any Cause
DaysAcalabrutinib + BSCBSC Alone
Time From Randomization to First Occurrence of Respiratory Failure or Death on Study Due to Any CauseNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Acalabrutinib + BSC vs BSC Alone · Regression, Cox · Hazard ratio (hr): 0.758 · 95% CI 0.323 to 1.722Adjusting for age (\<65 vs \>=65 years) and comorbidities (present vs absent). Ties handled by Efron approach. HR CI using profile likelihood approach.
SecondaryNumber of Days Alive and Free of Respiratory Failure

Respiratory failure, is defined based on resource utilization of any of the following modalities: a) Endotracheal intubation and mechanical ventilation b) Oxygen delivered by highflow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates \>20 L/min with fraction of delivered oxygen ≥0.5) c) Non-invasive positive pressure ventilation or continuous positive airway pressure d) Extracorporeal membrane oxygenation

Time frame:
From randomization to 28 days after randomization.
Reported as:
Mean · Days
Number of Days Alive and Free of Respiratory Failure
DaysAcalabrutinib + BSCBSC Alone
Number of Days Alive and Free of Respiratory Failure24.8 ± 8.025.3 ± 7.1
SecondaryNumber of Days With Respiratory Failure

Respiratory failure, is defined based on resource utilization of any of the following modalities: a) Endotracheal intubation and mechanical ventilation b) Oxygen delivered by high-flow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates \>20 L/min with fraction of delivered oxygen ≥0.5) c) Non-invasive positive pressure ventilation or continuous positive airway pressure d) Extracorporeal membrane oxygenation For participants who die (due to any cause) prior to Day 28, days from death to Day 28 are counted as days with respiratory failure. For participants in hospital and experiencing respiratory failure at the time they withdraw from the study, days from last known status to Day 28 are counted as days with respiratory failure.

Time frame:
From randomization to 28 days after randomization.
Reported as:
Mean · Days
Number of Days With Respiratory Failure
DaysAcalabrutinib + BSCBSC Alone
Number of Days With Respiratory Failure3.2 ± 8.02.7 ± 7.1
SecondaryNumber of Days Hospitalized

For this summary, the hospitalization must be considered clinically indicated to count as a day hospitalized. For participants who die (due to any cause) prior to Day 28, days from death to Day 28 are counted as days hospitalized. For participants in hospital at the time they withdraw from the study, days from last known status to Day 28 are counted as days hospitalized.

Time frame:
From randomization to 28 days after randomization.
Reported as:
Mean · Days
Number of Days Hospitalized
DaysAcalabrutinib + BSCBSC Alone
Number of Days Hospitalized12.2 ± 8.610.4 ± 7.4
SecondaryNumber of Days in ICU

For this summary, the ICU stay must be considered clinically indicated to count as a day in ICU. For participants who die (due to any cause) prior to Day 90, days from death to Day 90 are counted as days in ICU.

Time frame:
From randomization to 90 days after randomization.
Reported as:
Mean · Days
Number of Days in ICU
DaysAcalabrutinib + BSCBSC Alone
Number of Days in ICU10.4 ± 25.59.7 ± 25.8
SecondaryNumber of Days Alive Outside of Hospital
Time frame:
From randomization to 28 days after randomization.
Reported as:
Mean · Days
Number of Days Alive Outside of Hospital
DaysAcalabrutinib + BSCBSC Alone
Number of Days Alive Outside of Hospital15.1 ± 8.417.0 ± 7.3
SecondaryNumber of Days Alive Outside of Hospital
Time frame:
From randomization to 90 days after randomization.
Reported as:
Mean · Days
Number of Days Alive Outside of Hospital
DaysAcalabrutinib + BSCBSC Alone
Number of Days Alive Outside of Hospital66.8 ± 28.271.3 ± 24.5
SecondaryPercent Change From Baseline in Oxygenation Index

Baseline is defined as the result obtained on the date of randomization. Percent change from baseline at Day X is calculated by multiplying the following result by 100%: (Day X value - Baseline value)/Baseline value. The mean of this result for all analyzed patients is taken to get the mean percent change from baseline.

Time frame:
Days 3, 5, 7, 10, 14, 28
Reported as:
Mean · Percent change
Percent Change From Baseline in Oxygenation Index
Percent changeAcalabrutinib + BSCBSC Alone
Day 311.65 ± 29.4012.20 ± 33.88
Day 523.94 ± 41.7233.09 ± 51.50
Day 730.58 ± 57.7954.51 ± 84.75
Day 10/ Discharge (last post-baseline assessment if discharged from hospital prior to Day 10)54.25 ± 71.7162.10 ± 80.79
Day 1064.44 ± 84.0280.52 ± 101.48
Day 1470.39 ± 77.2783.71 ± 84.96
Day 2880.93 ± 89.6190.68 ± 95.43
SecondaryTime From Randomization to Clinical Improvement of at Least 2 Points on a 9-point Category Ordinal Scale

9-point category ordinal scale: 0. \* Uninfected, no clinical or virological evidence of infection 1. Ambulatory, no limitation of activities 2. Ambulatory, limitation of activities 3. Hospitalized - mild disease, no oxygen therapy 4. Hospitalized - mild disease, oxygen by mask or nasal prongs 5. Hospitalized - severe disease, non-invasive ventilation or high flow oxygen 6. Hospitalised - severe disease, intubation and mechanical ventilation 7. Hospitalized - severe disease, ventilation and additional organ support, such as pressors, renal replacement therapy, extracorporeal membrane oxygenation 8. Death Median time to first occurrence of respiratory failure or death, calculated using the Kaplan-Meier technique. Confidence interval for median overall survival (days) is derived based on Brookmeyer-Crowley method with log-log transformation.

Time frame:
From randomization to 28 days after randomization.
Reported as:
Median · Days
Time From Randomization to Clinical Improvement of at Least 2 Points on a 9-point Category Ordinal Scale
DaysAcalabrutinib + BSCBSC Alone
Time From Randomization to Clinical Improvement of at Least 2 Points on a 9-point Category Ordinal Scale10.00 (8.00 to 12.00)10.00 (8.00 to 11.00)
Statistical analysis
  • Acalabrutinib + BSC vs BSC Alone · Regression, Cox · Hazard ratio (hr): 0.967 · 95% CI 0.690 to 1.353Adjusting for age (\<65 vs \>=65 years) and comorbidities (present vs absent). Ties handled by Efron approach. HR CI using profile likelihood approach.
SecondaryPharmacokinetics of Acalabrutinib

Summary of plasma concentrations (ng/mL) of acalabrutinib

Time frame:
Day 3 and Day 7
Reported as:
Geometric mean · ng/mL
Pharmacokinetics of Acalabrutinib
ng/mLAcalabrutinib + BSC
Day 3, Pre-dose15.359 ± 195.1
Day 3, 0.5 hours post-dose54.580 ± 139.7
Day 3, 1 hour post-dose56.120 ± 141.6
Day 3, 2 hours post-dose90.173 ± 104.3
Day 3, 4 hours post-dose36.841 ± 179.2
Day 3, 6 hours post-dose23.551 ± 205.0
Day 7, 1 hour post-dose117.015 ± 60.3
Day 7, 4 hours post-dose17.454 ± 108.6
SecondaryPharmacokinetics of ACP-5862

Summary of plasma concentrations (ng/mL) of ACP-5862

Time frame:
Day 3 and Day 7
Reported as:
Geometric mean · ng/mL
Pharmacokinetics of ACP-5862
ng/mLAcalabrutinib + BSC
Day 3, Pre-dose71.526 ± 94.8
Day 3, 0.5 hours post-dose125.332 ± 109.9
Day 3, 1 hour post-dose144.784 ± 95.1
Day 3, 2 hours post-dose213.370 ± 72.7
Day 3, 4 hours post-dose154.437 ± 70.3
Day 3, 6 hours post-dose113.769 ± 82.8
Day 7, 1 hour post-dose156.133 ± 68.0
Day 7, 4 hours post-dose95.392 ± 69.7

Adverse events

Collected over Screening to 28 (+3) days after last dose of acalabrutinib (for acalabrutinib + BSC treated participants) or to 38 (+3) days after randomization (for BSC alone treated participants). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Acalabrutinib + BSC7/86 (8.1%)7/86 (8.1%)10/86 (11.6%)
BSC Alone10/91 (11%)2/91 (2.2%)2/91 (2.2%)
Most frequent serious events
Most frequent serious events
EventAcalabrutinib + BSCBSC Alone
PneumoniaInfections and infestations2/860/91
Respiratory failureRespiratory, thoracic and mediastinal disorders2/860/91
Bacterial sepsisInfections and infestations1/860/91
Mucosal infectionInfections and infestations1/860/91
Acute kidney injuryRenal and urinary disorders1/860/91
Pleural effusionRespiratory, thoracic and mediastinal disorders1/860/91
HypotensionVascular disorders1/860/91
Septic shockInfections and infestations0/861/91
Ischaemic strokeNervous system disorders0/861/91
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/861/91
Most frequent other events
Most frequent other events
EventAcalabrutinib + BSCBSC Alone
HeadacheNervous system disorders10/862/91

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Acalabrutinib + BSCBSC AloneTotal
Mean56.7 ± 13.356.7 ± 14.856.7 ± 14.1
Age, Customized
Age, Customized(Participants)Acalabrutinib + BSCBSC AloneTotal
< 65 years6160121
>= 65 years282856
Sex: Female, Male
Sex: Female, Male(Participants)Acalabrutinib + BSCBSC AloneTotal
Female292453
Male6064124
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Acalabrutinib + BSCBSC AloneTotal
HISPANIC OR LATINO484795
NOT HISPANIC OR LATINO414182
NOT REPORTED000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Acalabrutinib + BSCBSC AloneTotal
WHITE404888
BLACK OR AFRICAN AMERICAN358
AMERICAN INDIAN OR ALASKA NATIVE7310
ASIAN231336
NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER000
OTHER141933
NOT REPORTED202
08

Study locations

50 sites
  • Research Site
    Ciudad de Buenos Aires, 1221, Argentina
  • Research Site
    Ciudad de Buenos Aires, C1180AAX, Argentina
  • Research Site
    Monte Grande, B1842, Argentina
  • Research Site
    Ramos Mejía, B1704, Argentina
  • Research Site
    Botucatu, 18618-687, Brazil
  • Research Site
    Brasillia, 72145-450, Brazil
  • Research Site
    Florianópolis, 88036-800, Brazil
  • Research Site
    Porto Alegre, 90035-903, Brazil
  • Research Site
    Porto Alegre, 91350-200, Brazil
  • Research Site
    Ribeirão Preto, 14051-140, Brazil
  • Research Site
    Salvador, 40110-060, Brazil
  • Research Site
    Sao Bernardo do Campo, 09715090, Brazil
  • Research Site
    Sao Paulo, 01327-001, Brazil
  • Research Site
    Sao Paulo, 04004-030, Brazil
  • Research Site
    São Paulo, 01308-050, Brazil
  • Research Site
    Curico, 3341643, Chile
  • Research Site
    Santiago, 7500692, Chile
  • Research Site
    Talca, 3460001, Chile
  • Research Site
    Villejuif Cedex, 94805, France
  • Research Site
    Frankfurt, 60590, Germany
  • Research Site
    Gauting, 82131, Germany
  • Research Site
    Köln, 50937, Germany
  • Research Site
    Bangalore, 560002, India
  • Research Site
    New Delhi, 110017, India
  • Research Site
    Milano, 20132, Italy
  • Research Site
    Roma, 00168, Italy
  • Research Site
    Shinjuku-ku, 162-8655, Japan
  • Research Site
    D.F, 14050, Mexico
  • Research Site
    Monterrey, 64461, Mexico
  • Research Site
    México, 03103, Mexico
  • Research Site
    Lima, 15324, Peru
  • Research Site
    Lima, LIMA 11, Peru
  • Research Site
    Lima, LIMA 1, Peru
  • Research Site
    Warszawa, 02-507, Poland
  • Research Site
    Warszawa, 04-141, Poland
  • Research Site
    Moscow, 111539, Russian Federation
  • Research Site
    Moscow, 119992, Russian Federation
  • Research Site
    Moscow, 123182, Russian Federation
  • Research Site
    Moscow, 143442, Russian Federation
  • Research Site
    Murmansk, 183047, Russian Federation
  • Research Site
    Cape Town, 7500, South Africa
  • Research Site
    George, 6529, South Africa
  • Research Site
    Johannesburg, 1827, South Africa
  • Research Site
    Johannesburg, 2193, South Africa
  • Research Site
    Pretoria, 0157, South Africa
  • Research Site
    Ankara, 06800, Turkey
  • Research Site
    Bakirkoy, 34147, Turkey
  • Research Site
    Istanbul, 34214, Turkey
  • Research Site
    Istanbul, Turkey
  • Research Site
    Umraniye, 34760, Turkey
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Nov 2020, 5 months.

Results were first posted in Sep 2021, 9 months after primary completion.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 5 months is below that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2020
First posted
Apr 15, 2020
StartActual
Jun 12, 2020
Primary completionActual
Nov 17, 2020
CompletionActual
Nov 17, 2020
Results first posted
Sep 13, 2021
Last update
Sep 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04346199
Lead sponsor
AstraZeneca
Collaborators
Acerta Pharma BV
Responsible party
Sponsor
First posted
Apr 15, 2020
Start date
Jun 12, 2020
Primary completion
Nov 17, 2020
Completion
Nov 17, 2020
Results posted
Sep 13, 2021
Last update
Sep 17, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acalabrutinib

Start the discussion